Roivant Sciences (ROIV) Operating Income (2020 - 2026)

Roivant Sciences (ROIV) has reported Operating Income for 7 consecutive years, with -$366.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Operating Income fell 28.45% year-over-year to -$366.0 million; the trailing twelve-month figure through Jun 2026 stood at -$1.9 billion (down 30.42% YoY), and the FY2026 full-year result was -$515.1 million, up 48.66% from the prior year.
• Operating Income improved to -$366.0 million in Q2 2026 per ROIV's latest filing, from -$930.3 million in the prior quarter.
• Across five years, Operating Income topped out at $5.1 billion in Q4 2023 and bottomed at -$941.2 million in Q4 2022.
• Historically, Operating Income has averaged $6.4 million across 5 years, with a median of -$284.9 million in 2025.
• The sharpest annual moves came in 2023 and 2025: Operating Income surged 644.81% in 2023, then plunged 178.69% in 2025.
• Over 5 years, Operating Income stood at -$941.2 million in 2022, then soared by 644.81% to $5.1 billion in 2023, then sank by 114.01% to -$718.3 million in 2024, then decreased by 29.51% to -$930.3 million in 2025, then soared by 60.66% to -$366.0 million in 2026.
• According to Business Quant data, Operating Income over the past three periods registered -$366.0 million, -$930.3 million, and -$306.2 million for Q2 2026, Q4 2025, and Q3 2025 respectively.